Abstract
FACIL-VAA is a multicentre (35) prospective cohort of CSA eligible for ASV treatment that will collect real life clinical data from baseline to up to 7 years follow-up (FU).
Methods: From June 2017 to February 2020, 541 CSA patients (11,8% Women) were prospectively included. Systolic heart failure patient with left ventricular ejection fraction below 45% were not included. CSA was defined by an AHI>15/h and at least 50% of central respiratory events using full polysomnography or respiratory polygraphy. Patients were treated using one of the three existing ASV Brands according to physician preferences. Primary objective was change in Pittsburgh Sleep Quality Index (PSQI) at 6-month.
Results: Analysis in ITT was performed in 526 patients, women 11,8%, median age and BMI were 69 [59; 76] years and 28 [26; 32] kg/m², respectively. Patients exhibited severe CSA with a median AHI, ODI and T90 of 44 [31.8; 60] per hour, 38 [21.7; 54.3] per hour and 16.2 [2.1; 53.5] minutes respectively. Associated and overlapped comorbidities that may have participate to the CSA aetiology were cardiologic, neurologic or medication in 237 (45,1%), 105 (20%) and 35 (6,9%) patients respectively. CSA was not associated to any disease in 125 (23,8%) and related to a CPAP emergent CSA in 119 (22,6%) patients. PSQI improved in 63% of patients from 8 [5; 12] to 6 [4; 10], p<0.0001. PSQI improved significantly for all CSA aetiologies except drug induced CSA.
Conclusion: These results illustrate the efficacy of ASV in CSA and the need to perform extensive phenotyping since improvement of sleep quality is related to CSA aetiology.
Footnotes
Cite this article as Eur Respir J 2022; 60: Suppl. 66, 4688.
This article was presented at the 2022 ERS International Congress, in session “-”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2022
